nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP2C9—brain cancer	0.367	1	CbGaD
Lansoprazole—CYP1B1—Procarbazine—brain cancer	0.22	0.518	CbGbCtD
Lansoprazole—CYP2D6—Lomustine—brain cancer	0.0303	0.0711	CbGbCtD
Lansoprazole—CYP1A2—Carmustine—brain cancer	0.0299	0.0704	CbGbCtD
Lansoprazole—ABCG2—Carboplatin—brain cancer	0.0256	0.0603	CbGbCtD
Lansoprazole—CYP2D6—Hydroxyurea—brain cancer	0.0229	0.0539	CbGbCtD
Lansoprazole—CYP3A4—Temozolomide—brain cancer	0.0226	0.0532	CbGbCtD
Lansoprazole—ABCG2—Etoposide—brain cancer	0.0215	0.0506	CbGbCtD
Lansoprazole—CYP3A4—Lomustine—brain cancer	0.0192	0.0452	CbGbCtD
Lansoprazole—CYP2C8—Etoposide—brain cancer	0.0115	0.027	CbGbCtD
Lansoprazole—CYP1A2—Etoposide—brain cancer	0.00888	0.0209	CbGbCtD
Lansoprazole—ABCB1—Etoposide—brain cancer	0.00776	0.0182	CbGbCtD
Lansoprazole—CYP3A4—Etoposide—brain cancer	0.00465	0.0109	CbGbCtD
Lansoprazole—ATP4B—endocrine gland—brain cancer	0.00115	0.0694	CbGeAlD
Lansoprazole—Pantoprazole—CYP2C9—brain cancer	0.00114	0.355	CrCbGaD
Lansoprazole—Rabeprazole—CYP2C9—brain cancer	0.00114	0.355	CrCbGaD
Lansoprazole—MAPT—telencephalon—brain cancer	0.00107	0.0645	CbGeAlD
Lansoprazole—Omeprazole—CYP2C9—brain cancer	0.000931	0.29	CrCbGaD
Lansoprazole—MAPT—pituitary gland—brain cancer	0.000869	0.0525	CbGeAlD
Lansoprazole—MAPT—medulla oblongata—brain cancer	0.000839	0.0507	CbGeAlD
Lansoprazole—MAPT—midbrain—brain cancer	0.000767	0.0463	CbGeAlD
Lansoprazole—MAPT—spinal cord—brain cancer	0.000748	0.0452	CbGeAlD
Lansoprazole—CYP4A11—endocrine gland—brain cancer	0.00062	0.0375	CbGeAlD
Lansoprazole—MAPT—cerebellum—brain cancer	0.000593	0.0358	CbGeAlD
Lansoprazole—ATP4A—endocrine gland—brain cancer	0.0005	0.0302	CbGeAlD
Lansoprazole—ATP4A—head—brain cancer	0.000494	0.0298	CbGeAlD
Lansoprazole—MAPT—brain—brain cancer	0.000482	0.0291	CbGeAlD
Lansoprazole—ATP4A—central nervous system—brain cancer	0.000451	0.0272	CbGeAlD
Lansoprazole—ATP4A—cerebellum—brain cancer	0.00044	0.0266	CbGeAlD
Lansoprazole—CYP2C18—endocrine gland—brain cancer	0.000411	0.0248	CbGeAlD
Lansoprazole—CYP1A2—Tamoxifen metabolism—CYP2C9—brain cancer	0.000367	0.00552	CbGpPWpGaD
Lansoprazole—ATP4A—brain—brain cancer	0.000358	0.0216	CbGeAlD
Lansoprazole—CYP4A11—PPAR Alpha Pathway—CDK4—brain cancer	0.000344	0.00518	CbGpPWpGaD
Lansoprazole—CYP2C19—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000336	0.00506	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—S100A10—brain cancer	0.000335	0.00504	CbGpPWpGaD
Lansoprazole—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000328	0.00494	CbGpPWpGaD
Lansoprazole—CYP1B1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000327	0.00492	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic execution phase—APC—brain cancer	0.000321	0.00484	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—APC—brain cancer	0.000321	0.00484	CbGpPWpGaD
Lansoprazole—CYP2D6—hindbrain—brain cancer	0.000317	0.0191	CbGeAlD
Lansoprazole—CYP1B1—telencephalon—brain cancer	0.000316	0.0191	CbGeAlD
Lansoprazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000312	0.0047	CbGpPWpGaD
Lansoprazole—ABCG2—Irinotecan Pathway—APC—brain cancer	0.000312	0.00469	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—S100A10—brain cancer	0.000298	0.00449	CbGpPWpGaD
Lansoprazole—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.000294	0.00443	CbGpPWpGaD
Lansoprazole—CYP1A1—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000287	0.00433	CbGpPWpGaD
Lansoprazole—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.000283	0.00426	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic cleavage of cellular proteins—CTNNB1—brain cancer	0.000281	0.00422	CbGpPWpGaD
Lansoprazole—MAPT—IL-5 Signaling Pathway—IL2—brain cancer	0.000279	0.0042	CbGpPWpGaD
Lansoprazole—CYP4A11—Biological oxidations—CYP2C9—brain cancer	0.00027	0.00406	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—IL2—brain cancer	0.000268	0.00404	CbGpPWpGaD
Lansoprazole—CYP2C8—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000263	0.00397	CbGpPWpGaD
Lansoprazole—CYP1B1—gonad—brain cancer	0.000263	0.0159	CbGeAlD
Lansoprazole—CYP1B1—pituitary gland—brain cancer	0.000257	0.0155	CbGeAlD
Lansoprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000249	0.00375	CbGpPWpGaD
Lansoprazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000248	0.00374	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.000247	0.00372	CbGpPWpGaD
Lansoprazole—CYP1A1—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000245	0.00369	CbGpPWpGaD
Lansoprazole—ABCB1—blood vessel—brain cancer	0.000239	0.0144	CbGeAlD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000236	0.00356	CbGpPWpGaD
Lansoprazole—CYP2C18—Biological oxidations—CYP2C9—brain cancer	0.000236	0.00355	CbGpPWpGaD
Lansoprazole—CYP2C19—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000235	0.00354	CbGpPWpGaD
Lansoprazole—ABCG2—telencephalon—brain cancer	0.000235	0.0142	CbGeAlD
Lansoprazole—MAPT—IL-5 Signaling Pathway—STAT3—brain cancer	0.000235	0.00353	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.000235	0.00353	CbGpPWpGaD
Lansoprazole—CYP2C18—Metapathway biotransformation—CYP2C9—brain cancer	0.000232	0.0035	CbGpPWpGaD
Lansoprazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000228	0.00343	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—STAT3—brain cancer	0.000226	0.0034	CbGpPWpGaD
Lansoprazole—CYP2C8—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000225	0.00338	CbGpPWpGaD
Lansoprazole—CYP4A11—PPAR Alpha Pathway—CCND1—brain cancer	0.000222	0.00334	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—CCND1—brain cancer	0.00022	0.00332	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic execution phase—CTNNB1—brain cancer	0.000218	0.00329	CbGpPWpGaD
Lansoprazole—MAPT—IL-5 Signaling Pathway—MYC—brain cancer	0.000218	0.00328	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-2-alpha transcription factor network—SIRT1—brain cancer	0.000215	0.00324	CbGpPWpGaD
Lansoprazole—CYP1B1—Estrogen Receptor Pathway—STAT3—brain cancer	0.000215	0.00324	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—RELA—brain cancer	0.000213	0.0032	CbGpPWpGaD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.000211	0.00317	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—MYC—brain cancer	0.00021	0.00316	CbGpPWpGaD
Lansoprazole—MAPT—LKB1 signaling events—MYC—brain cancer	0.000206	0.0031	CbGpPWpGaD
Lansoprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000203	0.00306	CbGpPWpGaD
Lansoprazole—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000202	0.00304	CbGpPWpGaD
Lansoprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000201	0.00303	CbGpPWpGaD
Lansoprazole—CYP2C19—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000201	0.00302	CbGpPWpGaD
Lansoprazole—CYP1B1—endocrine gland—brain cancer	0.000199	0.012	CbGeAlD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.000198	0.00298	CbGpPWpGaD
Lansoprazole—CYP2C8—pituitary gland—brain cancer	0.000197	0.0119	CbGeAlD
Lansoprazole—CYP1B1—head—brain cancer	0.000197	0.0119	CbGeAlD
Lansoprazole—MAPT—Notch Signaling Pathway—CCND1—brain cancer	0.000194	0.00292	CbGpPWpGaD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000193	0.0029	CbGpPWpGaD
Lansoprazole—ABCG2—pituitary gland—brain cancer	0.000191	0.0116	CbGeAlD
Lansoprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000187	0.00281	CbGpPWpGaD
Lansoprazole—ABCG2—medulla oblongata—brain cancer	0.000185	0.0112	CbGeAlD
Lansoprazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000185	0.00278	CbGpPWpGaD
Lansoprazole—CYP2D6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000184	0.00278	CbGpPWpGaD
Lansoprazole—CYP1A2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000183	0.00276	CbGpPWpGaD
Lansoprazole—CYP2D6—brainstem—brain cancer	0.000182	0.011	CbGeAlD
Lansoprazole—CYP1B1—central nervous system—brain cancer	0.000179	0.0108	CbGeAlD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.000179	0.0027	CbGpPWpGaD
Lansoprazole—CYP4A11—PPAR Alpha Pathway—MYC—brain cancer	0.000178	0.00268	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—SPP1—brain cancer	0.000178	0.00268	CbGpPWpGaD
Lansoprazole—CYP1B1—cerebellum—brain cancer	0.000175	0.0106	CbGeAlD
Lansoprazole—CYP2C19—endocrine gland—brain cancer	0.000175	0.0105	CbGeAlD
Lansoprazole—CYP1B1—Biological oxidations—CYP2C9—brain cancer	0.000174	0.00261	CbGpPWpGaD
Lansoprazole—MAPT—Kit receptor signaling pathway—STAT3—brain cancer	0.000172	0.00259	CbGpPWpGaD
Lansoprazole—CYP1B1—Metapathway biotransformation—CYP2C9—brain cancer	0.000171	0.00258	CbGpPWpGaD
Lansoprazole—MAPT—LKB1 signaling events—TP53—brain cancer	0.000169	0.00254	CbGpPWpGaD
Lansoprazole—ABCG2—midbrain—brain cancer	0.000169	0.0102	CbGeAlD
Lansoprazole—MAPT—Notch Signaling Pathway—STAT3—brain cancer	0.000168	0.00252	CbGpPWpGaD
Lansoprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000165	0.00248	CbGpPWpGaD
Lansoprazole—ABCG2—spinal cord—brain cancer	0.000165	0.00994	CbGeAlD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	0.000163	0.00245	CbGpPWpGaD
Lansoprazole—Hallucination—Carmustine—brain cancer	0.000162	0.00134	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—IRS2—brain cancer	0.000161	0.00242	CbGpPWpGaD
Lansoprazole—CYP2D6—telencephalon—brain cancer	0.000161	0.00973	CbGeAlD
Lansoprazole—Decreased appetite—Procarbazine—brain cancer	0.00016	0.00133	CcSEcCtD
Lansoprazole—Alanine aminotransferase increased—Etoposide—brain cancer	0.00016	0.00132	CcSEcCtD
Lansoprazole—Oedema peripheral—Carmustine—brain cancer	0.00016	0.00132	CcSEcCtD
Lansoprazole—Connective tissue disorder—Carmustine—brain cancer	0.00016	0.00132	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	0.000159	0.0024	CbGpPWpGaD
Lansoprazole—Fatigue—Procarbazine—brain cancer	0.000159	0.00131	CcSEcCtD
Lansoprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000158	0.00238	CbGpPWpGaD
Lansoprazole—Malaise—Hydroxyurea—brain cancer	0.000158	0.0013	CcSEcCtD
Lansoprazole—Pain—Procarbazine—brain cancer	0.000158	0.0013	CcSEcCtD
Lansoprazole—Constipation—Procarbazine—brain cancer	0.000158	0.0013	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	0.000157	0.00237	CbGpPWpGaD
Lansoprazole—Hepatitis—Temozolomide—brain cancer	0.000157	0.0013	CcSEcCtD
Lansoprazole—Dysphagia—Etoposide—brain cancer	0.000157	0.0013	CcSEcCtD
Lansoprazole—Leukopenia—Hydroxyurea—brain cancer	0.000156	0.00129	CcSEcCtD
Lansoprazole—Visual impairment—Carmustine—brain cancer	0.000156	0.00129	CcSEcCtD
Lansoprazole—CYP1A2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000156	0.00235	CbGpPWpGaD
Lansoprazole—Hypoaesthesia—Temozolomide—brain cancer	0.000156	0.00129	CcSEcCtD
Lansoprazole—Hallucination—Temozolomide—brain cancer	0.000156	0.00129	CcSEcCtD
Lansoprazole—Pharyngitis—Temozolomide—brain cancer	0.000156	0.00129	CcSEcCtD
Lansoprazole—MAPT—Notch Signaling Pathway—MYC—brain cancer	0.000156	0.00234	CbGpPWpGaD
Lansoprazole—CYP1A1—Oxidative Stress—SOD2—brain cancer	0.000155	0.00233	CbGpPWpGaD
Lansoprazole—Urinary tract disorder—Temozolomide—brain cancer	0.000155	0.00128	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000155	0.00233	CbGpPWpGaD
Lansoprazole—Oedema peripheral—Temozolomide—brain cancer	0.000155	0.00128	CcSEcCtD
Lansoprazole—Connective tissue disorder—Temozolomide—brain cancer	0.000154	0.00128	CcSEcCtD
Lansoprazole—Urethral disorder—Temozolomide—brain cancer	0.000154	0.00127	CcSEcCtD
Lansoprazole—CYP2C8—endocrine gland—brain cancer	0.000152	0.00921	CbGeAlD
Lansoprazole—Feeling abnormal—Procarbazine—brain cancer	0.000152	0.00126	CcSEcCtD
Lansoprazole—Eye disorder—Carmustine—brain cancer	0.000152	0.00125	CcSEcCtD
Lansoprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000152	0.00228	CbGpPWpGaD
Lansoprazole—Convulsion—Hydroxyurea—brain cancer	0.000151	0.00125	CcSEcCtD
Lansoprazole—Visual impairment—Temozolomide—brain cancer	0.000151	0.00125	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Procarbazine—brain cancer	0.000151	0.00125	CcSEcCtD
Lansoprazole—Pancytopenia—Etoposide—brain cancer	0.000149	0.00123	CcSEcCtD
Lansoprazole—Erythema multiforme—Temozolomide—brain cancer	0.000148	0.00123	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000148	0.00122	CcSEcCtD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.000148	0.00222	CbGpPWpGaD
Lansoprazole—Discomfort—Hydroxyurea—brain cancer	0.000147	0.00122	CcSEcCtD
Lansoprazole—Neutropenia—Etoposide—brain cancer	0.000147	0.00121	CcSEcCtD
Lansoprazole—Eye disorder—Temozolomide—brain cancer	0.000147	0.00121	CcSEcCtD
Lansoprazole—MAPT—LPA receptor mediated events—EGFR—brain cancer	0.000147	0.00221	CbGpPWpGaD
Lansoprazole—Urticaria—Procarbazine—brain cancer	0.000146	0.00121	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	0.000146	0.0022	CbGpPWpGaD
Lansoprazole—Tinnitus—Temozolomide—brain cancer	0.000146	0.00121	CcSEcCtD
Lansoprazole—Abdominal pain—Procarbazine—brain cancer	0.000146	0.00121	CcSEcCtD
Lansoprazole—Body temperature increased—Procarbazine—brain cancer	0.000146	0.00121	CcSEcCtD
Lansoprazole—Cardiac disorder—Temozolomide—brain cancer	0.000146	0.0012	CcSEcCtD
Lansoprazole—MAPT—Copper homeostasis—TP53—brain cancer	0.000145	0.00219	CbGpPWpGaD
Lansoprazole—Arrhythmia—Carmustine—brain cancer	0.000145	0.0012	CcSEcCtD
Lansoprazole—Alopecia—Carmustine—brain cancer	0.000143	0.00119	CcSEcCtD
Lansoprazole—Oedema—Hydroxyurea—brain cancer	0.000143	0.00118	CcSEcCtD
Lansoprazole—CYP1A2—endocrine gland—brain cancer	0.000143	0.00862	CbGeAlD
Lansoprazole—CYP1B1—brain—brain cancer	0.000142	0.0086	CbGeAlD
Lansoprazole—Angiopathy—Temozolomide—brain cancer	0.000142	0.00118	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—APC—brain cancer	0.000142	0.00214	CbGpPWpGaD
Lansoprazole—Mental disorder—Carmustine—brain cancer	0.000142	0.00118	CcSEcCtD
Lansoprazole—Infection—Hydroxyurea—brain cancer	0.000142	0.00117	CcSEcCtD
Lansoprazole—Immune system disorder—Temozolomide—brain cancer	0.000142	0.00117	CcSEcCtD
Lansoprazole—Mediastinal disorder—Temozolomide—brain cancer	0.000141	0.00117	CcSEcCtD
Lansoprazole—Erythema—Carmustine—brain cancer	0.000141	0.00117	CcSEcCtD
Lansoprazole—Malnutrition—Carmustine—brain cancer	0.000141	0.00117	CcSEcCtD
Lansoprazole—Chills—Temozolomide—brain cancer	0.000141	0.00116	CcSEcCtD
Lansoprazole—CYP1A1—endocrine gland—brain cancer	0.000141	0.0085	CbGeAlD
Lansoprazole—Pneumonia—Etoposide—brain cancer	0.000141	0.00116	CcSEcCtD
Lansoprazole—Nervous system disorder—Hydroxyurea—brain cancer	0.00014	0.00116	CcSEcCtD
Lansoprazole—Infestation NOS—Etoposide—brain cancer	0.00014	0.00116	CcSEcCtD
Lansoprazole—Infestation—Etoposide—brain cancer	0.00014	0.00116	CcSEcCtD
Lansoprazole—Thrombocytopenia—Hydroxyurea—brain cancer	0.00014	0.00116	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	0.000139	0.0021	CbGpPWpGaD
Lansoprazole—CYP1A1—head—brain cancer	0.000139	0.00839	CbGeAlD
Lansoprazole—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000139	0.00115	CcSEcCtD
Lansoprazole—Alopecia—Temozolomide—brain cancer	0.000139	0.00115	CcSEcCtD
Lansoprazole—Skin disorder—Hydroxyurea—brain cancer	0.000139	0.00115	CcSEcCtD
Lansoprazole—Acute coronary syndrome—Etoposide—brain cancer	0.000138	0.00114	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000138	0.00207	CbGpPWpGaD
Lansoprazole—Renal failure—Etoposide—brain cancer	0.000137	0.00114	CcSEcCtD
Lansoprazole—Mental disorder—Temozolomide—brain cancer	0.000137	0.00114	CcSEcCtD
Lansoprazole—Myocardial infarction—Etoposide—brain cancer	0.000137	0.00113	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Etoposide—brain cancer	0.000137	0.00113	CcSEcCtD
Lansoprazole—Back pain—Carmustine—brain cancer	0.000137	0.00113	CcSEcCtD
Lansoprazole—Malnutrition—Temozolomide—brain cancer	0.000137	0.00113	CcSEcCtD
Lansoprazole—Erythema—Temozolomide—brain cancer	0.000137	0.00113	CcSEcCtD
Lansoprazole—Stomatitis—Etoposide—brain cancer	0.000136	0.00113	CcSEcCtD
Lansoprazole—Jaundice—Etoposide—brain cancer	0.000136	0.00113	CcSEcCtD
Lansoprazole—Anorexia—Hydroxyurea—brain cancer	0.000136	0.00112	CcSEcCtD
Lansoprazole—Hypersensitivity—Procarbazine—brain cancer	0.000136	0.00112	CcSEcCtD
Lansoprazole—CYP2C9—endocrine gland—brain cancer	0.000135	0.00818	CbGeAlD
Lansoprazole—MAPT—Apoptosis—APC—brain cancer	0.000134	0.00202	CbGpPWpGaD
Lansoprazole—Dysgeusia—Temozolomide—brain cancer	0.000134	0.00111	CcSEcCtD
Lansoprazole—Vision blurred—Carmustine—brain cancer	0.000133	0.0011	CcSEcCtD
Lansoprazole—CYP1A1—Estrogen Receptor Pathway—STAT3—brain cancer	0.000133	0.002	CbGpPWpGaD
Lansoprazole—Tremor—Carmustine—brain cancer	0.000132	0.0011	CcSEcCtD
Lansoprazole—Asthenia—Procarbazine—brain cancer	0.000132	0.00109	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Etoposide—brain cancer	0.000132	0.00109	CcSEcCtD
Lansoprazole—Back pain—Temozolomide—brain cancer	0.000132	0.00109	CcSEcCtD
Lansoprazole—Anaemia—Carmustine—brain cancer	0.000131	0.00108	CcSEcCtD
Lansoprazole—ABCG2—cerebellum—brain cancer	0.000131	0.00788	CbGeAlD
Lansoprazole—Agranulocytosis—Etoposide—brain cancer	0.00013	0.00108	CcSEcCtD
Lansoprazole—Pruritus—Procarbazine—brain cancer	0.00013	0.00108	CcSEcCtD
Lansoprazole—Agitation—Carmustine—brain cancer	0.00013	0.00107	CcSEcCtD
Lansoprazole—Vision blurred—Temozolomide—brain cancer	0.000129	0.00106	CcSEcCtD
Lansoprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000128	0.00193	CbGpPWpGaD
Lansoprazole—Tremor—Temozolomide—brain cancer	0.000128	0.00106	CcSEcCtD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000128	0.00192	CbGpPWpGaD
Lansoprazole—Dyspnoea—Hydroxyurea—brain cancer	0.000127	0.00105	CcSEcCtD
Lansoprazole—Somnolence—Hydroxyurea—brain cancer	0.000127	0.00105	CcSEcCtD
Lansoprazole—CYP1A1—central nervous system—brain cancer	0.000127	0.00766	CbGeAlD
Lansoprazole—Ill-defined disorder—Temozolomide—brain cancer	0.000127	0.00105	CcSEcCtD
Lansoprazole—Leukopenia—Carmustine—brain cancer	0.000126	0.00105	CcSEcCtD
Lansoprazole—Anaemia—Temozolomide—brain cancer	0.000126	0.00104	CcSEcCtD
Lansoprazole—Diarrhoea—Procarbazine—brain cancer	0.000126	0.00104	CcSEcCtD
Lansoprazole—Dyspepsia—Hydroxyurea—brain cancer	0.000126	0.00104	CcSEcCtD
Lansoprazole—Agitation—Temozolomide—brain cancer	0.000125	0.00104	CcSEcCtD
Lansoprazole—Hypoaesthesia—Etoposide—brain cancer	0.000125	0.00103	CcSEcCtD
Lansoprazole—Angioedema—Temozolomide—brain cancer	0.000125	0.00103	CcSEcCtD
Lansoprazole—Decreased appetite—Hydroxyurea—brain cancer	0.000124	0.00103	CcSEcCtD
Lansoprazole—Urinary tract disorder—Etoposide—brain cancer	0.000124	0.00103	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000123	0.00102	CcSEcCtD
Lansoprazole—Malaise—Temozolomide—brain cancer	0.000123	0.00102	CcSEcCtD
Lansoprazole—Urethral disorder—Etoposide—brain cancer	0.000123	0.00102	CcSEcCtD
Lansoprazole—Fatigue—Hydroxyurea—brain cancer	0.000123	0.00102	CcSEcCtD
Lansoprazole—Vertigo—Temozolomide—brain cancer	0.000123	0.00101	CcSEcCtD
Lansoprazole—Convulsion—Carmustine—brain cancer	0.000122	0.00101	CcSEcCtD
Lansoprazole—Leukopenia—Temozolomide—brain cancer	0.000122	0.00101	CcSEcCtD
Lansoprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000122	0.00184	CbGpPWpGaD
Lansoprazole—Hypertension—Carmustine—brain cancer	0.000122	0.00101	CcSEcCtD
Lansoprazole—Constipation—Hydroxyurea—brain cancer	0.000122	0.00101	CcSEcCtD
Lansoprazole—Pain—Hydroxyurea—brain cancer	0.000122	0.00101	CcSEcCtD
Lansoprazole—Dizziness—Procarbazine—brain cancer	0.000122	0.00101	CcSEcCtD
Lansoprazole—Palpitations—Temozolomide—brain cancer	0.000121	0.000998	CcSEcCtD
Lansoprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000121	0.00182	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	0.000121	0.00181	CbGpPWpGaD
Lansoprazole—Chest pain—Carmustine—brain cancer	0.00012	0.000995	CcSEcCtD
Lansoprazole—Myalgia—Carmustine—brain cancer	0.00012	0.000995	CcSEcCtD
Lansoprazole—Anxiety—Carmustine—brain cancer	0.00012	0.000992	CcSEcCtD
Lansoprazole—Cough—Temozolomide—brain cancer	0.000119	0.000986	CcSEcCtD
Lansoprazole—Erythema multiforme—Etoposide—brain cancer	0.000119	0.000982	CcSEcCtD
Lansoprazole—Convulsion—Temozolomide—brain cancer	0.000118	0.000979	CcSEcCtD
Lansoprazole—Hypertension—Temozolomide—brain cancer	0.000118	0.000975	CcSEcCtD
Lansoprazole—Feeling abnormal—Hydroxyurea—brain cancer	0.000118	0.000973	CcSEcCtD
Lansoprazole—Eye disorder—Etoposide—brain cancer	0.000117	0.00097	CcSEcCtD
Lansoprazole—Vomiting—Procarbazine—brain cancer	0.000117	0.00097	CcSEcCtD
Lansoprazole—Cardiac disorder—Etoposide—brain cancer	0.000117	0.000964	CcSEcCtD
Lansoprazole—Confusional state—Carmustine—brain cancer	0.000116	0.000962	CcSEcCtD
Lansoprazole—Myalgia—Temozolomide—brain cancer	0.000116	0.000962	CcSEcCtD
Lansoprazole—Arthralgia—Temozolomide—brain cancer	0.000116	0.000962	CcSEcCtD
Lansoprazole—Rash—Procarbazine—brain cancer	0.000116	0.000961	CcSEcCtD
Lansoprazole—Dermatitis—Procarbazine—brain cancer	0.000116	0.000961	CcSEcCtD
Lansoprazole—ABCB1—telencephalon—brain cancer	0.000116	0.007	CbGeAlD
Lansoprazole—Anxiety—Temozolomide—brain cancer	0.000116	0.000958	CcSEcCtD
Lansoprazole—Headache—Procarbazine—brain cancer	0.000115	0.000955	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000115	0.000955	CcSEcCtD
Lansoprazole—Oedema—Carmustine—brain cancer	0.000115	0.000954	CcSEcCtD
Lansoprazole—Discomfort—Temozolomide—brain cancer	0.000115	0.00095	CcSEcCtD
Lansoprazole—Infection—Carmustine—brain cancer	0.000115	0.000948	CcSEcCtD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.000114	0.00171	CbGpPWpGaD
Lansoprazole—Angiopathy—Etoposide—brain cancer	0.000114	0.000942	CcSEcCtD
Lansoprazole—Dry mouth—Temozolomide—brain cancer	0.000114	0.000941	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—APC—brain cancer	0.000114	0.00171	CbGpPWpGaD
Lansoprazole—Immune system disorder—Etoposide—brain cancer	0.000113	0.000938	CcSEcCtD
Lansoprazole—Mediastinal disorder—Etoposide—brain cancer	0.000113	0.000936	CcSEcCtD
Lansoprazole—Thrombocytopenia—Carmustine—brain cancer	0.000113	0.000934	CcSEcCtD
Lansoprazole—Body temperature increased—Hydroxyurea—brain cancer	0.000113	0.000933	CcSEcCtD
Lansoprazole—Chills—Etoposide—brain cancer	0.000113	0.000932	CcSEcCtD
Lansoprazole—Tachycardia—Carmustine—brain cancer	0.000113	0.000931	CcSEcCtD
Lansoprazole—Confusional state—Temozolomide—brain cancer	0.000112	0.00093	CcSEcCtD
Lansoprazole—Anaphylactic shock—Temozolomide—brain cancer	0.000111	0.000922	CcSEcCtD
Lansoprazole—Oedema—Temozolomide—brain cancer	0.000111	0.000922	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—RELA—brain cancer	0.000111	0.00167	CbGpPWpGaD
Lansoprazole—Alopecia—Etoposide—brain cancer	0.000111	0.000918	CcSEcCtD
Lansoprazole—Infection—Temozolomide—brain cancer	0.000111	0.000916	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.00011	0.00166	CbGpPWpGaD
Lansoprazole—Anorexia—Carmustine—brain cancer	0.00011	0.000909	CcSEcCtD
Lansoprazole—Nausea—Procarbazine—brain cancer	0.000109	0.000906	CcSEcCtD
Lansoprazole—Nervous system disorder—Temozolomide—brain cancer	0.000109	0.000904	CcSEcCtD
Lansoprazole—Thrombocytopenia—Temozolomide—brain cancer	0.000109	0.000903	CcSEcCtD
Lansoprazole—CYP2C8—brain—brain cancer	0.000109	0.00659	CbGeAlD
Lansoprazole—Skin disorder—Temozolomide—brain cancer	0.000108	0.000896	CcSEcCtD
Lansoprazole—Hypotension—Carmustine—brain cancer	0.000108	0.000891	CcSEcCtD
Lansoprazole—Hyperhidrosis—Temozolomide—brain cancer	0.000108	0.000891	CcSEcCtD
Lansoprazole—Dysgeusia—Etoposide—brain cancer	0.000107	0.000885	CcSEcCtD
Lansoprazole—CYP1A1—Biological oxidations—CYP2C9—brain cancer	0.000107	0.00161	CbGpPWpGaD
Lansoprazole—Anorexia—Temozolomide—brain cancer	0.000106	0.000879	CcSEcCtD
Lansoprazole—ABCG2—brain—brain cancer	0.000106	0.0064	CbGeAlD
Lansoprazole—Back pain—Etoposide—brain cancer	0.000106	0.000874	CcSEcCtD
Lansoprazole—CYP1A1—Metapathway biotransformation—CYP2C9—brain cancer	0.000105	0.00159	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Hydroxyurea—brain cancer	0.000105	0.000869	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Carmustine—brain cancer	0.000105	0.000869	CcSEcCtD
Lansoprazole—Muscle spasms—Etoposide—brain cancer	0.000105	0.000869	CcSEcCtD
Lansoprazole—Insomnia—Carmustine—brain cancer	0.000104	0.000863	CcSEcCtD
Lansoprazole—MAPT—Alzheimers Disease—TP53—brain cancer	0.000104	0.00156	CbGpPWpGaD
Lansoprazole—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.000104	0.00156	CbGpPWpGaD
Lansoprazole—Paraesthesia—Carmustine—brain cancer	0.000104	0.000857	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000103	0.00156	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—RELA—brain cancer	0.000103	0.00156	CbGpPWpGaD
Lansoprazole—CYP3A4—endocrine gland—brain cancer	0.000103	0.00624	CbGeAlD
Lansoprazole—Dyspnoea—Carmustine—brain cancer	0.000103	0.000851	CcSEcCtD
Lansoprazole—Somnolence—Carmustine—brain cancer	0.000103	0.000848	CcSEcCtD
Lansoprazole—Asthenia—Hydroxyurea—brain cancer	0.000102	0.000847	CcSEcCtD
Lansoprazole—CYP2D6—endocrine gland—brain cancer	0.000102	0.00614	CbGeAlD
Lansoprazole—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000102	0.00084	CcSEcCtD
Lansoprazole—Ill-defined disorder—Etoposide—brain cancer	0.000101	0.000839	CcSEcCtD
Lansoprazole—Anaemia—Etoposide—brain cancer	0.000101	0.000835	CcSEcCtD
Lansoprazole—Insomnia—Temozolomide—brain cancer	0.000101	0.000834	CcSEcCtD
Lansoprazole—CYP1A1—brain—brain cancer	0.000101	0.00608	CbGeAlD
Lansoprazole—CYP2D6—head—brain cancer	0.0001	0.00606	CbGeAlD
Lansoprazole—Decreased appetite—Carmustine—brain cancer	0.0001	0.000829	CcSEcCtD
Lansoprazole—Paraesthesia—Temozolomide—brain cancer	0.0001	0.000828	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Carmustine—brain cancer	9.96e-05	0.000824	CcSEcCtD
Lansoprazole—Dyspnoea—Temozolomide—brain cancer	9.94e-05	0.000822	CcSEcCtD
Lansoprazole—Somnolence—Temozolomide—brain cancer	9.91e-05	0.00082	CcSEcCtD
Lansoprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	9.91e-05	0.00149	CbGpPWpGaD
Lansoprazole—Constipation—Carmustine—brain cancer	9.86e-05	0.000816	CcSEcCtD
Lansoprazole—Pain—Carmustine—brain cancer	9.86e-05	0.000816	CcSEcCtD
Lansoprazole—Malaise—Etoposide—brain cancer	9.85e-05	0.000815	CcSEcCtD
Lansoprazole—Vertigo—Etoposide—brain cancer	9.82e-05	0.000812	CcSEcCtD
Lansoprazole—Dyspepsia—Temozolomide—brain cancer	9.81e-05	0.000812	CcSEcCtD
Lansoprazole—CYP2C8—Biological oxidations—CYP2C9—brain cancer	9.81e-05	0.00148	CbGpPWpGaD
Lansoprazole—Leukopenia—Etoposide—brain cancer	9.78e-05	0.000809	CcSEcCtD
Lansoprazole—Diarrhoea—Hydroxyurea—brain cancer	9.76e-05	0.000807	CcSEcCtD
Lansoprazole—Decreased appetite—Temozolomide—brain cancer	9.69e-05	0.000801	CcSEcCtD
Lansoprazole—CYP2C8—Metapathway biotransformation—CYP2C9—brain cancer	9.67e-05	0.00146	CbGpPWpGaD
Lansoprazole—ABCB1—gonad—brain cancer	9.67e-05	0.00584	CbGeAlD
Lansoprazole—MAPT—BDNF signaling pathway—CTNNB1—brain cancer	9.67e-05	0.00145	CbGpPWpGaD
Lansoprazole—Gastrointestinal disorder—Temozolomide—brain cancer	9.62e-05	0.000796	CcSEcCtD
Lansoprazole—Fatigue—Temozolomide—brain cancer	9.61e-05	0.000795	CcSEcCtD
Lansoprazole—Loss of consciousness—Etoposide—brain cancer	9.6e-05	0.000794	CcSEcCtD
Lansoprazole—Cough—Etoposide—brain cancer	9.54e-05	0.000789	CcSEcCtD
Lansoprazole—Constipation—Temozolomide—brain cancer	9.53e-05	0.000788	CcSEcCtD
Lansoprazole—Pain—Temozolomide—brain cancer	9.53e-05	0.000788	CcSEcCtD
Lansoprazole—Feeling abnormal—Carmustine—brain cancer	9.5e-05	0.000786	CcSEcCtD
Lansoprazole—Convulsion—Etoposide—brain cancer	9.47e-05	0.000783	CcSEcCtD
Lansoprazole—Hypertension—Etoposide—brain cancer	9.43e-05	0.00078	CcSEcCtD
Lansoprazole—ABCB1—pituitary gland—brain cancer	9.43e-05	0.0057	CbGeAlD
Lansoprazole—Dizziness—Hydroxyurea—brain cancer	9.43e-05	0.00078	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Carmustine—brain cancer	9.43e-05	0.00078	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	9.31e-05	0.0014	CbGpPWpGaD
Lansoprazole—CYP3A4—central nervous system—brain cancer	9.3e-05	0.00562	CbGeAlD
Lansoprazole—Chest pain—Etoposide—brain cancer	9.3e-05	0.00077	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	9.24e-05	0.000764	CcSEcCtD
Lansoprazole—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	9.21e-05	0.00139	CbGpPWpGaD
Lansoprazole—Discomfort—Etoposide—brain cancer	9.19e-05	0.00076	CcSEcCtD
Lansoprazole—Feeling abnormal—Temozolomide—brain cancer	9.18e-05	0.00076	CcSEcCtD
Lansoprazole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—brain cancer	9.16e-05	0.00138	CbGpPWpGaD
Lansoprazole—CYP2D6—central nervous system—brain cancer	9.16e-05	0.00553	CbGeAlD
Lansoprazole—Abdominal pain—Carmustine—brain cancer	9.12e-05	0.000754	CcSEcCtD
Lansoprazole—Body temperature increased—Carmustine—brain cancer	9.12e-05	0.000754	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Temozolomide—brain cancer	9.11e-05	0.000754	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—CTNNB1—brain cancer	9.11e-05	0.00137	CbGpPWpGaD
Lansoprazole—ABCB1—medulla oblongata—brain cancer	9.1e-05	0.0055	CbGeAlD
Lansoprazole—Vomiting—Hydroxyurea—brain cancer	9.07e-05	0.00075	CcSEcCtD
Lansoprazole—Rash—Hydroxyurea—brain cancer	9e-05	0.000744	CcSEcCtD
Lansoprazole—Confusional state—Etoposide—brain cancer	8.99e-05	0.000744	CcSEcCtD
Lansoprazole—Dermatitis—Hydroxyurea—brain cancer	8.99e-05	0.000743	CcSEcCtD
Lansoprazole—CYP2D6—cerebellum—brain cancer	8.95e-05	0.0054	CbGeAlD
Lansoprazole—Headache—Hydroxyurea—brain cancer	8.94e-05	0.000739	CcSEcCtD
Lansoprazole—Anaphylactic shock—Etoposide—brain cancer	8.92e-05	0.000738	CcSEcCtD
Lansoprazole—Infection—Etoposide—brain cancer	8.86e-05	0.000733	CcSEcCtD
Lansoprazole—Urticaria—Temozolomide—brain cancer	8.85e-05	0.000732	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	8.81e-05	0.00133	CbGpPWpGaD
Lansoprazole—Abdominal pain—Temozolomide—brain cancer	8.81e-05	0.000729	CcSEcCtD
Lansoprazole—Body temperature increased—Temozolomide—brain cancer	8.81e-05	0.000729	CcSEcCtD
Lansoprazole—CYP2C19—Biological oxidations—CYP2C9—brain cancer	8.75e-05	0.00132	CbGpPWpGaD
Lansoprazole—Thrombocytopenia—Etoposide—brain cancer	8.73e-05	0.000722	CcSEcCtD
Lansoprazole—Tachycardia—Etoposide—brain cancer	8.7e-05	0.00072	CcSEcCtD
Lansoprazole—Skin disorder—Etoposide—brain cancer	8.66e-05	0.000717	CcSEcCtD
Lansoprazole—CYP2C19—Metapathway biotransformation—CYP2C9—brain cancer	8.63e-05	0.0013	CbGpPWpGaD
Lansoprazole—Hyperhidrosis—Etoposide—brain cancer	8.62e-05	0.000713	CcSEcCtD
Lansoprazole—Anorexia—Etoposide—brain cancer	8.5e-05	0.000703	CcSEcCtD
Lansoprazole—Hypersensitivity—Carmustine—brain cancer	8.5e-05	0.000703	CcSEcCtD
Lansoprazole—Nausea—Hydroxyurea—brain cancer	8.47e-05	0.000701	CcSEcCtD
Lansoprazole—CYP1A2—Estrogen Receptor Pathway—STAT3—brain cancer	8.45e-05	0.00127	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—STAT3—brain cancer	8.43e-05	0.00127	CbGpPWpGaD
Lansoprazole—Hypotension—Etoposide—brain cancer	8.33e-05	0.000689	CcSEcCtD
Lansoprazole—ABCB1—midbrain—brain cancer	8.32e-05	0.00503	CbGeAlD
Lansoprazole—Asthenia—Carmustine—brain cancer	8.27e-05	0.000684	CcSEcCtD
Lansoprazole—Hypersensitivity—Temozolomide—brain cancer	8.21e-05	0.000679	CcSEcCtD
Lansoprazole—ABCB1—spinal cord—brain cancer	8.12e-05	0.0049	CbGeAlD
Lansoprazole—CYP2D6—Biological oxidations—CYP2C9—brain cancer	8.05e-05	0.00121	CbGpPWpGaD
Lansoprazole—Paraesthesia—Etoposide—brain cancer	8.01e-05	0.000662	CcSEcCtD
Lansoprazole—Asthenia—Temozolomide—brain cancer	8e-05	0.000661	CcSEcCtD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	7.98e-05	0.0012	CbGpPWpGaD
Lansoprazole—Dyspnoea—Etoposide—brain cancer	7.95e-05	0.000658	CcSEcCtD
Lansoprazole—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	7.94e-05	0.00119	CbGpPWpGaD
Lansoprazole—Somnolence—Etoposide—brain cancer	7.93e-05	0.000656	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	7.91e-05	0.00119	CbGpPWpGaD
Lansoprazole—Diarrhoea—Carmustine—brain cancer	7.89e-05	0.000653	CcSEcCtD
Lansoprazole—Pruritus—Temozolomide—brain cancer	7.89e-05	0.000652	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	7.79e-05	0.00117	CbGpPWpGaD
Lansoprazole—Decreased appetite—Etoposide—brain cancer	7.75e-05	0.000641	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	7.71e-05	0.00116	CbGpPWpGaD
Lansoprazole—Gastrointestinal disorder—Etoposide—brain cancer	7.7e-05	0.000637	CcSEcCtD
Lansoprazole—Fatigue—Etoposide—brain cancer	7.69e-05	0.000636	CcSEcCtD
Lansoprazole—Dizziness—Carmustine—brain cancer	7.63e-05	0.000631	CcSEcCtD
Lansoprazole—Constipation—Etoposide—brain cancer	7.63e-05	0.000631	CcSEcCtD
Lansoprazole—Pain—Etoposide—brain cancer	7.63e-05	0.000631	CcSEcCtD
Lansoprazole—Diarrhoea—Temozolomide—brain cancer	7.63e-05	0.000631	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—IDH1—brain cancer	7.57e-05	0.00114	CbGpPWpGaD
Lansoprazole—Dizziness—Temozolomide—brain cancer	7.37e-05	0.00061	CcSEcCtD
Lansoprazole—Feeling abnormal—Etoposide—brain cancer	7.35e-05	0.000608	CcSEcCtD
Lansoprazole—Vomiting—Carmustine—brain cancer	7.33e-05	0.000607	CcSEcCtD
Lansoprazole—ABCB1—endocrine gland—brain cancer	7.31e-05	0.00441	CbGeAlD
Lansoprazole—Gastrointestinal pain—Etoposide—brain cancer	7.29e-05	0.000603	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—MYC—brain cancer	7.28e-05	0.0011	CbGpPWpGaD
Lansoprazole—Rash—Carmustine—brain cancer	7.27e-05	0.000602	CcSEcCtD
Lansoprazole—CYP2D6—brain—brain cancer	7.27e-05	0.00439	CbGeAlD
Lansoprazole—Dermatitis—Carmustine—brain cancer	7.27e-05	0.000601	CcSEcCtD
Lansoprazole—Headache—Carmustine—brain cancer	7.23e-05	0.000598	CcSEcCtD
Lansoprazole—ABCB1—head—brain cancer	7.22e-05	0.00436	CbGeAlD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	7.12e-05	0.00107	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—brain cancer	7.12e-05	0.00107	CbGpPWpGaD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—TP53—brain cancer	7.09e-05	0.00107	CbGpPWpGaD
Lansoprazole—Vomiting—Temozolomide—brain cancer	7.09e-05	0.000586	CcSEcCtD
Lansoprazole—Urticaria—Etoposide—brain cancer	7.08e-05	0.000586	CcSEcCtD
Lansoprazole—Abdominal pain—Etoposide—brain cancer	7.05e-05	0.000583	CcSEcCtD
Lansoprazole—Body temperature increased—Etoposide—brain cancer	7.05e-05	0.000583	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	7.03e-05	0.00106	CbGpPWpGaD
Lansoprazole—Rash—Temozolomide—brain cancer	7.03e-05	0.000581	CcSEcCtD
Lansoprazole—Dermatitis—Temozolomide—brain cancer	7.02e-05	0.000581	CcSEcCtD
Lansoprazole—Headache—Temozolomide—brain cancer	6.98e-05	0.000578	CcSEcCtD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—S100A10—brain cancer	6.96e-05	0.00105	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—MYC—brain cancer	6.92e-05	0.00104	CbGpPWpGaD
Lansoprazole—Nausea—Carmustine—brain cancer	6.85e-05	0.000567	CcSEcCtD
Lansoprazole—CYP1A2—Biological oxidations—CYP2C9—brain cancer	6.82e-05	0.00103	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	6.79e-05	0.00102	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—EGFR—brain cancer	6.77e-05	0.00102	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	6.73e-05	0.00101	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	6.67e-05	0.001	CbGpPWpGaD
Lansoprazole—Nausea—Temozolomide—brain cancer	6.62e-05	0.000548	CcSEcCtD
Lansoprazole—ABCB1—central nervous system—brain cancer	6.59e-05	0.00398	CbGeAlD
Lansoprazole—Hypersensitivity—Etoposide—brain cancer	6.57e-05	0.000544	CcSEcCtD
Lansoprazole—ABCB1—cerebellum—brain cancer	6.44e-05	0.00389	CbGeAlD
Lansoprazole—Asthenia—Etoposide—brain cancer	6.4e-05	0.000529	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—RELA—brain cancer	6.36e-05	0.000958	CbGpPWpGaD
Lansoprazole—Pruritus—Etoposide—brain cancer	6.31e-05	0.000522	CcSEcCtD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	6.29e-05	0.000947	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	6.25e-05	0.00094	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	6.11e-05	0.000919	CbGpPWpGaD
Lansoprazole—Diarrhoea—Etoposide—brain cancer	6.1e-05	0.000505	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—TP53—brain cancer	6.06e-05	0.000912	CbGpPWpGaD
Lansoprazole—Dizziness—Etoposide—brain cancer	5.9e-05	0.000488	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	5.73e-05	0.000863	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TP53—brain cancer	5.68e-05	0.000855	CbGpPWpGaD
Lansoprazole—Vomiting—Etoposide—brain cancer	5.67e-05	0.000469	CcSEcCtD
Lansoprazole—Rash—Etoposide—brain cancer	5.62e-05	0.000465	CcSEcCtD
Lansoprazole—Dermatitis—Etoposide—brain cancer	5.62e-05	0.000465	CcSEcCtD
Lansoprazole—Headache—Etoposide—brain cancer	5.59e-05	0.000462	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—PDGFRA—brain cancer	5.44e-05	0.000819	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—brain cancer	5.39e-05	0.000811	CbGpPWpGaD
Lansoprazole—Nausea—Etoposide—brain cancer	5.3e-05	0.000438	CcSEcCtD
Lansoprazole—CYP3A4—Biological oxidations—CYP2C9—brain cancer	5.26e-05	0.000792	CbGpPWpGaD
Lansoprazole—ABCB1—brain—brain cancer	5.23e-05	0.00316	CbGeAlD
Lansoprazole—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	5.19e-05	0.000781	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	5.13e-05	0.000772	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	4.88e-05	0.000734	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	4.87e-05	0.000733	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CYP2C9—brain cancer	4.61e-05	0.000694	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	4.54e-05	0.000683	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—brain cancer	4.48e-05	0.000675	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—brain cancer	4.38e-05	0.00066	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	4.38e-05	0.00066	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	4.3e-05	0.000648	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	4.11e-05	0.000618	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	4.06e-05	0.000611	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CYP2C9—brain cancer	4.03e-05	0.000606	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—BSG—brain cancer	3.92e-05	0.00059	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.77e-05	0.000567	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	3.76e-05	0.000567	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	3.65e-05	0.00055	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	3.63e-05	0.000547	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—BSG—brain cancer	3.43e-05	0.000516	CbGpPWpGaD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	3.4e-05	0.000512	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—IDH1—brain cancer	3.37e-05	0.000507	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.36e-05	0.000506	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—TRPC6—brain cancer	3.22e-05	0.000484	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	3.11e-05	0.000467	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3e-05	0.000452	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	2.98e-05	0.000449	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL2—brain cancer	2.97e-05	0.000447	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CYP2C9—brain cancer	2.97e-05	0.000447	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—IDH1—brain cancer	2.95e-05	0.000443	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	2.93e-05	0.00044	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	2.91e-05	0.000439	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	2.89e-05	0.000435	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	2.86e-05	0.00043	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	2.8e-05	0.000421	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	2.8e-05	0.000421	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.75e-05	0.000414	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.74e-05	0.000413	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CYP2C9—brain cancer	2.7e-05	0.000407	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	2.69e-05	0.000404	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ENO2—brain cancer	2.66e-05	0.000401	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.62e-05	0.000394	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	2.56e-05	0.000385	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—BSG—brain cancer	2.53e-05	0.00038	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—VEGFA—brain cancer	2.52e-05	0.00038	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.46e-05	0.00037	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ENO2—brain cancer	2.33e-05	0.00035	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—BSG—brain cancer	2.3e-05	0.000346	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.24e-05	0.000337	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	2.21e-05	0.000333	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—IDH1—brain cancer	2.17e-05	0.000327	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	2.08e-05	0.000313	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—IDH1—brain cancer	1.98e-05	0.000297	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.91e-05	0.000288	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CYP2C9—brain cancer	1.83e-05	0.000275	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.77e-05	0.000266	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	1.74e-05	0.000262	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ENO2—brain cancer	1.72e-05	0.000258	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CYP2C9—brain cancer	1.68e-05	0.000252	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	1.62e-05	0.000243	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ENO2—brain cancer	1.56e-05	0.000235	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—BSG—brain cancer	1.56e-05	0.000234	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CYP2C9—brain cancer	1.5e-05	0.000225	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CYP2C9—brain cancer	1.46e-05	0.00022	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	1.43e-05	0.000215	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—BSG—brain cancer	1.43e-05	0.000215	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	1.41e-05	0.000213	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CYP2C9—brain cancer	1.38e-05	0.000207	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—IDH1—brain cancer	1.34e-05	0.000201	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—BSG—brain cancer	1.27e-05	0.000192	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	1.25e-05	0.000187	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—BSG—brain cancer	1.24e-05	0.000187	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—IDH1—brain cancer	1.23e-05	0.000185	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PIK3CG—brain cancer	1.22e-05	0.000184	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—BSG—brain cancer	1.17e-05	0.000176	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CYP2C9—brain cancer	1.17e-05	0.000176	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—BSG—brain cancer	1.16e-05	0.000175	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	1.15e-05	0.000172	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	1.12e-05	0.000169	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—IDH1—brain cancer	1.09e-05	0.000165	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.09e-05	0.000164	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—IDH1—brain cancer	1.07e-05	0.000161	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PIK3CG—brain cancer	1.07e-05	0.000161	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ENO2—brain cancer	1.06e-05	0.000159	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—IDH1—brain cancer	1.01e-05	0.000152	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.98e-06	0.00015	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—IDH1—brain cancer	9.98e-06	0.00015	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—BSG—brain cancer	9.92e-06	0.000149	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ENO2—brain cancer	9.69e-06	0.000146	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	9.41e-06	0.000142	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CYP2C9—brain cancer	9e-06	0.000135	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	8.91e-06	0.000134	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ENO2—brain cancer	8.65e-06	0.00013	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—IDH1—brain cancer	8.53e-06	0.000128	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ENO2—brain cancer	8.44e-06	0.000127	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	8.13e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ENO2—brain cancer	7.96e-06	0.00012	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ENO2—brain cancer	7.89e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PIK3CG—brain cancer	7.87e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—BSG—brain cancer	7.65e-06	0.000115	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PIK3CG—brain cancer	7.16e-06	0.000108	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	6.94e-06	0.000105	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ENO2—brain cancer	6.74e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—IDH1—brain cancer	6.58e-06	9.91e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ENO2—brain cancer	5.2e-06	7.83e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PIK3CG—brain cancer	4.85e-06	7.3e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PIK3CG—brain cancer	4.45e-06	6.69e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PIK3CG—brain cancer	3.97e-06	5.97e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PIK3CG—brain cancer	3.87e-06	5.83e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PIK3CG—brain cancer	3.65e-06	5.49e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PIK3CG—brain cancer	3.62e-06	5.45e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PIK3CG—brain cancer	3.09e-06	4.65e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PIK3CG—brain cancer	2.39e-06	3.59e-05	CbGpPWpGaD
